Skip to Content
Merck
CN

SML3925

Liraglutide

≥95% (HPLC), GLP-1 receptor agonist, Powder or Lyophilized powder or film

Synonym(s):

Arg34, Lys26-[Nε(γ-Glu[Nα-hexadecanoyl])]-GLP-1[7-37], H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-N6-[N-(1-oxohexadecyl)-L-γ-glutamyl]-Lys-α-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH, HAEGTFTSDVSSYLEGQAA-N6-[N-(1-oxohexadecyl)-L-γ-glutamyl]K-EFIAWLVRGRG, NN2211

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C172H265N43O51
CAS Number:
204656-20-2
Molecular Weight:
3751.20
UNSPSC Code:
51111800
NACRES:
NA.77

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Liraglutide, ≥95% (HPLC)

assay

≥95% (HPLC)

form

(Powder or Lyophilized powder or film)

color

white to off-white

storage temp.

-10 to -25°C

Quality Level

100

Related Categories

Biochem/physiol Actions

Glucagon-like peptide-1 (GLP-1)-based incretin mimetic with enhanced in vivo stability and efficacy against type 2 diabetes and obesity.
Liraglutide (NN2211) is a glucagon-like peptide-1 (GLP-1)-based incretin mimetic (cAMP stimulation EC50 = 61 nM vs 55 nM with GLP-1(7-37) using human GLP-1 receptor-expressing BHK cells), where GLP-1(7-37) sequence is modified with a Lys34-to-Arg substitution and a γ-Glu-C16 acylation on Lys26 for enhanced in vivo stability (plasma t1/2 in pigs post s.c. = 14 h vs 1.2 h with GLP-1(7-37)) and efficacy against type 2 diabetes and obesity (400 μg/kg/day s.c. in rats; 100-200 μg/kg bid or single 50-200 μg/kg i.v. in rats; 100 μg/kg bid or single 30-1000 μg/kg s.c. in mice; 2 μg/kg i.v. or 3.3 μg/kg/day s.c. in pigs).

pictograms

Health hazardExclamation mark
GHS08,GHS07

signalword

Warning

Storage Class

11 - Combustible Solids

wgk

WGK 3

Hazard Classifications

Acute Tox. 4 Oral - Repr. 2

Regulatory Information

涉药品监管产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000516652
0000516648
0000493184
0000493184
0000447110

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Liraglutide improves cognitive impairment via the AMPK and PI3K/Akt signaling pathways in type 2 diabetic rats
Molecular Medicine Reports, 18(2), 2449-2457 (2018)
The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice
American Journal of Physiology. Endocrinology and Metabolism, 283(4), E745-E752 (2002)
GLP-1 Analogue Liraglutide Enhances SP-A Expression in LPS-Induced Acute Lung Injury through the TTF-1 Signaling Pathway
Mediators of Inflammation, 2018, 3601454-3601454 (2018)
NN2211: a long-acting glucagon-like peptide-1 derivative with anti-diabetic effects in glucose-intolerant pigs
European Journal of Pharmacology, 451(2), 217-225 (2002)
Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration
Journal of Medicinal Chemistry, 43(9), 1664-1669 (2000)
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service